From the Doctor's Corner: How does ACTM reduce the risks for PI ?
From the “Doctor’s Corner” (By Lanny Turner, M.D., Chief Medical Officer, Circlebase)

From the Doctor's Corner: How does ACTM reduce the risks for PI ?

From the “Doctor’s Corner” (By Lanny Turner, M.D., Chief Medical Officer, Circlebase)

As a clinician and a trials investigator, I’ve made several limited observations that are both encouraging and concerning, all at the same time. I have had the growing sense that many of the existing workflows required for clinical trials are, at best, disjointed and prone to inefficiencies and recording errors. For example, there are the current approaches used to identify and pre-qualify trial participants for study inclusion, and there are many of these. Among them is the employment of social media such as Facebook, in-house recruiters, third-party recruiters, review of databases from previous trials participation, and use of existing private practice patients (to name but a few) especially concerning the responsible principal investigator (PI) who is most at risk.

Sometimes the demographics have not been thoroughly examined. Other times, the prospective participants come to the investigator with obvious disqualifications based on their inability to meet the study’s inclusion/exclusion criteria. Then there is the large issue of sustainment of study participants, which has been cited by many as one of the two or three greatest causes of the inability of a study site to meet its target numbers. Each dropout and the failure-to-finish participant is costly, both to the sponsoring pharma entity and the site conducting the trial.

At this point, I wish to thank my own passionate development team at Circlebase for creating an elegant solution that addresses these issues. They’ve appropriately named this solution, the “Circlebase ACTM” (“Automated Clinical Trial Matching”). I will leave it to the reader to explore more of the power of this solution at our website, Circlebase.com. In a word, it is a collection of functionalities that automatically improve the rapid selection of a sustainable cohort for virtually any study. In doing so, each potential participant is evaluated by comparing his/her own health information against the study’ specific inclusion/exclusion criteria. It does so by completing a simultaneous automated review of the patient’s health record, including both structured and unstructured data drawn from virtually any EHR. Doing so makes for optimal accuracy in identifying specific participants with the highest match score, thus reducing the number of patients who fail their actual enrollment encounter or later drop out. The beauty of this solution is that because it utilizes NLP (natural language processing), ML (machine learning), and the requisite ontologies, it becomes ever more “intelligent” as it is used.

Most importantly, our ACTM product accomplishes these improved recruitment and sustainment functions using an automated platform, and its inherent efficiencies are reflected as increased revenue for the customer. I have only introduced our ACTM in this blog. However, our team is zealous about the power of this product, and we would appreciate the opportunity to further demonstrate this at a time convenient for you. To schedule a brief introduction and demo, please contact us at [email protected]

All the best and more to come!

Lanny Turner, M.D. Circlebase CMO




Jessica Brodie

Writer, editor SC United Methodist Advocate, blogger. Agent Bob Hostetler/The Steve Laube Agency. JessicaBrodie.com

2 年

Great piece. Well done!

回复

要查看或添加评论,请登录

Circlebase的更多文章

社区洞察

其他会员也浏览了